Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 17/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL557460 | 0.99 | REN (0.41) | RENCYP3A4KCNH2AKT1ROCK2 | |
| SCHEMBL556652 | 0.85 | P2RX7 (0.38) | RENCYP3A4KCNH2AKT1P2RX7 | |
| SCHEMBL7874645 | 0.85 | P2RX7 (0.38) | RENCYP3A4KCNH2AKT1P2RX7 | |
| SCHEMBL556706 | 0.80 | P2RX7 (0.36) | RENCYP3A4KCNH2P2RX7 | |
| Hydrochloric Acid SCHEMBL557461 | 0.76 | REN (0.42) | RENCYP3A4KCNH2AKT1ROCK2 | |
| SCHEMBL7864439 | 0.74 | P2RX7 (0.40) | KCNH2P2RX7 | |
| SCHEMBL556511 | 0.74 | P2RX7 (0.33) | CYP3A4AKT1P2RX7 | |
| SCHEMBL556510 | 0.73 | NTRK1 (0.35) | AKT1P2RX7 | |
| SCHEMBL19702118 | 0.61 | KDM1A (0.51) | AKT1ROCK2 | |
| SCHEMBL21404000 | 0.61 | KDM1A (0.51) | AKT1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 766/4885KCNH2 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.